Apixaban in patients with atrial fibrillation - The New England Journal of Medicine - 2011
Brief Summary:
In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin.Reference: http://www.ncbi.nlm.nih.gov/pubmed/21309657
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you